No Data
No Data
Jin Kai Shengke (301509.SZ): Currently, the cooperation with Eli Lilly does not involve diet medicine programs
Gelonghui, May 28 | Jinkai Shengke (301509.SZ) said on the investor interactive platform that the company's current cooperation with Eli Lilly does not involve diet medicine projects. The company always actively monitors customer business developments and strives to expand and promote business in line with its own development.
Jinkai Shengke (301509.SZ): As of May 20, 2024, the total number of shareholders of the company was 1,2041
Gelonghui, May 21丨Jinkai Shengke (301509.SZ) said on the investor interactive platform that as of May 20, 2024, the total number of shareholders of the company was 1,2041.
Jinkai Biotech (301509.SZ): The company currently has no business cooperation with Novavax Pharmaceuticals
GLONGHUI May 15 | Jinkai Biotech (301509.SZ) said on the investor interactive platform that the company currently has no business cooperation with Novavax Pharmaceuticals.
Jin Kai Shengke (301509.SZ): The company's product line covers various diseases such as cardiovascular, oncology, nervous system, and antiviral diseases
Gelonghui, May 15 | Jinkai Biotech (301509.SZ) said on the investor interactive platform that as a small molecule CDMO service provider, the company provides customized R&D and production services for small molecule drug intermediates and small quantities of APIs for new drug R&D projects at original pharmaceutical companies around the world. The company's product line covers various diseases such as cardiovascular, oncology, nervous system, and antiviral diseases.
Jinkai Shengke (301509.SZ): Has the technical ability of chiral synthesis
Gelonghui, May 15 | Jinkai Shengke (301509.SZ) said on the investor interactive platform that the company has the technical capability of chiral synthesis. Through chiral synthesis technology, it can control the selectivity of stereosomers during the reaction process, thereby generating new products with specific three-dimensional configurations. The company's expertise in chiral synthesis can provide customized R&D and production services for original pharmaceutical companies around the world to help customers solve the challenges of chiral synthesis in the new drug development process, thereby speeding up the marketing process of new drugs.
Jinkai Shengke (301509.SZ): An intermediate supplier for the simeglutide oral penetration enhancer SNAC
Gelonghui, May 15 | Jinkai Biotech (301509.SZ) said on the investor interactive platform that the company is a small molecule CDMO service provider for global life science customers, providing customized R&D and production services for small molecule drug intermediates and small quantities of APIs for the new drug R&D projects of original pharmaceutical companies around the world. The company is an intermediate supplier for simeglutide oral penetration enhancer SNAC. The company has always insisted on deepening technology, continuously consolidating its main business, and striving to promote the company's high-quality and sustainable development.
No Data